Atara Biotherapeutics Stock Jumps 18% as FDA Shake-Up Puts Ebvallo Back in Focus
Atara Biotherapeutics jumped roughly 18% late Monday morning, rallying alongside other rare-disease biotech stocks after word got out that the FDA’s head of biologics is set to depart next month. uniQure picked up about 15%, while Regenxbio climbed close to 20%. This is significant: Atara remains in pursuit of a U.S. route for EBVALLO, also known as tabelecleucel, a cell therapy targeting Epstein-Barr virus-positive post-transplant lymphoproliferative disease. The condition—rare, frequently deadly—can turn up after organ or stem-cell transplants, and, right now, there are no approved therapies for it in the U.S.
